The EMEA and the FDA estimate the benefit of bevacizumab (Avastin) in breast cancer different one.
The AkdÄ in 2008 has been critical to the approval of bevacizumab in combination with paclitaxel in metastatic breast cancer and shares the concerns of the FDA. From the perspective of AkdÄ should be approved in Europe continues to be used very cautiously in breast cancer combined. The affected patients should be advised of the expected marginal benefit and the rare but serious side effects before an individual decision is made for this treatment option.
Source:
AKdÄ News of 10 February 2011
0 comments:
Post a Comment